Human CD30 Ligand/TNFSF8/CD 30-L enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 2.05 pg/ml (50 μl)；9.27 pg/ml (10 μl)； |
| Standard Curve Range | 31.25 ~2000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0596 | 0.0705 | 0.0651 | |
| 31.25 | 0.1439 | 0.1665 | 0.1552 | 0.0902 |
| 62.50 | 0.2245 | 0.2592 | 0.2419 | 0.1768 |
| 125.00 | 0.3960 | 0.4307 | 0.4134 | 0.3483 |
| 250.00 | 0.7496 | 0.8006 | 0.7751 | 0.7101 |
| 500.00 | 1.3630 | 1.3900 | 1.3765 | 1.3115 |
| 1000.00 | 2.3260 | 2.5400 | 2.4330 | 2.3680 |
| 2000.00 | 3.9380 | 4.0608 | 3.9994 | 3.9344 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 24.8 | 166.3 | 576.3 | 28.0 | 174.4 | 581.4 |
| Standard Deviation | 1.9 | 8.2 | 24.8 | 1.5 | 3.7 | 14.1 |
| Coefficient of Variation(%) | 7.7 | 4.9 | 4.3 | 5.5 | 2.1 | 2.4 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CD30 Ligand/TNFSF8/CD 30-L into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 89% to 110% with an overall mean recovery of 101%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Human Serum | 30 | 197.54-394.71 | 100 | 297.34 |
Serum/Plasma– Thirty samples from apparently healthy volunteers/mouse serum were evaluated for the presence of human CD30 Ligand/TNFSF8/CD 30-L in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: CD30 Ligand/TNFSF8/CD 30-L
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a costimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.
